Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Hypertrophy-focused Resistance Training.
- Who it may be relevant to
- Registry conditions: Healthy Volunteers, Muscle Hypertrophy, Glycolysis, Moderately Trainend. Basic parameters: 18 years — 39 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Finland, Germany, Ireland, Spain
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
HyperLa: Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training: A Multi-centre Study by the HyperLa Study Group
Overview
The HyperLa study investigates whether a person's "glycolyticness"-the efficiency with which their body uses glycolysis for energy-can predict how much their muscles will grow (hypertrophy) in response to resistance training. Participants will undergo a specialized "vLapeak" test, which measures the maximal rate of lactate accumulation during a 10-second all-out cycling sprint, to determine their individual glycolytic power. Following this initial assessment, participants will complete eight weeks of standardized, twice-weekly resistance training focused on the lower body. The study aims to determine if individuals with higher initial vLapeak values experience greater increases in muscle size compared to those with lower values. This research may help explain why people respond differently to exercise and support the development of personalized training programs.
Detailed description
This multicentre, prospective, single-arm interventional cohort study aims to link metabolic phenotypes with physical adaptations.
* Primary Assessment: Glycolytic power is quantified via the vLapeak test, defined as the peak rate of blood lactate accumulation during a 10-second isokinetic or sprint-configured cycle ergometry test. * Intervention: The 8-week resistance training program consists of two supervised sessions per week. Exercises include the leg press (or Smith-machine squat) and leg extensions, performed for 4 sets of 8-12 repetitions. Intensity progresses from an RPE of 6 to voluntary muscular failure by the third week. * Measurements: Muscle hypertrophy is primarily assessed via ultrasound measurement of muscle thickness and cross-sectional area (CSA) of the thigh muscles before and after the intervention. * Secondary Objectives: The study also evaluates changes in the plasma metabolome via venous blood samples and, at select sites, analyzes muscle biopsies for glycolytic enzyme activity and fiber type composition to further validate the vLapeak results.
Interventions
- Behavioral Hypertrophy-focused Resistance Training
Standardized training consisting of twice-weekly supervised sessions for 8 weeks. Each session includes 4 sets of 8-12 repetitions of leg press (or Smith-machine squat) and leg extensions. Training intensity progresses from an RPE of 6 to voluntary muscular failure starting from week three.
Primary outcome measures
- Change in mid-thigh Muscle Thickness [Time frame: Baseline and Week 8 (completion of training intervention)]
- Change in lateral-thigh Muscle Thickness [Time frame: Baseline and Week 8 (completion of training intervention)]
Secondary outcome measures (5)
- Change in Peak Rate of Blood Lactate Accumulation (vLapeak) [Time frame: Baseline and Week 8 (completion of training intervention)]
- Change in Vastus Lateralis Muscle Cross-Sectional Area (CSA) [Time frame: Baseline and Week 8 (completion of training intervention)]
- Maximal Strength (3RM) for Leg Press [Time frame: Baseline and Week 8 (completion of training intervention)]
- Maximal Strength (3RM) for Leg Exentsion [Time frame: Baseline and Week 8 (completion of training intervention)]
- Change in Relative Abundance of Selected Plasma Metabolites [Time frame: Baseline and Week 8 (completion of training intervention)]
Eligibility criteria
Inclusion criteria
- Body Mass Index (BMI) between 20-29 kg/m2
- No structured resistance training performed in the last twelve months.
- Maximum of four sessions per week of recreational or low-to-moderate aerobic endurance activity.
- No history of competitive strength or physique sports.
Exclusion criteria
- Diagnosed cardiovascular, pulmonary, metabolic, neuromuscular, or orthopaedic disease that contraindicates exercise.
- Positive response to any question on the PAR-Q 2025 questionnaire.
- Current use of anabolic steroids, creatine, or other substances known to strongly influence muscle hypertrophy.
- Regular engagement in shift work.
- Women who are pregnant or breastfeeding.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Germany · 5 centers
- Technical University of Munich, TUM School of Medicine and Health — München
- DLR Cologne, Department of Metabolism and Human Performance — Cologne
- iST University of Applied Sciences — Düsseldorf
- TU Chemnitz, Sports Medicine and Exercise Therapy — Chemnitz
- Institute for Applied Training Science (IAT) Leipzig — Leipzig
Finland · 1 center
- University of Jyväskylä, Faculty of Sport and Health Sciences — Jyväskylä
Ireland · 1 center
- University of Limerick, Department of Physical Education and Sport Sciences (PESS) — Limerick
Spain · 1 center
- Universidad Politécnica de Madrid, Facultad de Ciencias de la Actividad Física y del Depor — Madrid
Publications
- Ahtiainen JP, Walker S, Peltonen H, Holviala J, Sillanpaa E, Karavirta L, Sallinen J, Mikkola J, Valkeinen H, Mero A, Hulmi JJ, Hakkinen K. Heterogeneity in resistance training-induced muscle strength and mass responses in men and women of different ages. Age (Dordr). 2016 Feb;38(1):10. doi: 10.1007/s11357-015-9870-1. Epub 2016 Jan 15. PMID 26767377
- Wackerhage H, Kabasakalis A, Seiler S, Heck H. Is the vLamax for Glycolysis What the V O 2 max is for Oxidative Phosphorylation? Sports Med. 2025 Aug;55(8):1853-1866. doi: 10.1007/s40279-025-02259-6. Epub 2025 Jul 17. PMID 40676393
- Wackerhage H, Vechetti IJ, Baumert P, Gehlert S, Becker L, Jaspers RT, de Angelis MH. Does a Hypertrophying Muscle Fibre Reprogramme its Metabolism Similar to a Cancer Cell? Sports Med. 2022 Nov;52(11):2569-2578. doi: 10.1007/s40279-022-01676-1. Epub 2022 Apr 23. PMID 35460513
- Warburg O, Wind F, Negelein E. THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 1927 Mar 7;8(6):519-30. doi: 10.1085/jgp.8.6.519. No abstract available. PMID 19872213
Identifiers
NCT: NCT07721766 · HyperLa